Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seroquel XR approved for maintenance treatment

Executive Summary

AstraZeneca's once-daily Seroquel XR (quetiapine fumarate) is approved Nov. 15 for maintenance treatment of schizophrenia in adult patients. The once-daily atypical antipsychotic agent was first approved in May 2007 for acute treatment of schizophrenia. AstraZeneca hopes to get approval for treatment of bipolar disorder, major depressive disorder and generalized anxiety disorder by next October. AstraZeneca plans to use Seroquel XR to drive the growth of the total franchise, and not simply switch patients from the immediate-release product to the sustained-release regimen (1"The Pink Sheet" Nov. 5, 2007, p. 3)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS049057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel